Effects of a High-Fat Diet on Spontaneous Metastasis of Lewis Lung Carcinoma in Plasminogen Activator Inhibitor-1 Deficient and Wild-Type Mice

Lin Yan*, Lana C. DeMars

Introduction

Plasminogen activator inhibitor-1 (PAI-1), a serine protease inhibitor, is a major component of the urokinase plasminogen activation system. It is the principal inhibitor of urokinase-type plasminogen activator (uPA) that catalyzes the conversion of latent plasminogen to plasmin, which is responsible for proteolysis of extracellular matrix during cancer invasion and metastasis. Paradoxically, PAI-1 may participate in the pathophysiology of cancer progression, because elevated PAI-1 expression in primary tumors is associated with poor prognosis and substantially increased risk of recurrence [1,2]. Laboratory studies have found that PAI-1 promotes tumor growth [3] and experimental metastasis [4] and that depletion of PAI-1 inhibits tumor growth [5], invasion and vascularization [6] and metastasis [7]. However, others have reported that PAI-1 did not affect tumor growth [8] and metastasis [8,9].

Recurrent or metastatic cancer, the spread of malignant cells from a primary tumor to different sites of the same organ or to distant organs, remains the most devastating aspect of cancer. Its occurrence directly affects the prognosis and survival of cancer patients, presenting a great challenge not only for cancer patients but also for physicians and researchers. Metastasis is a multistep process, from dissemination of malignant cells from a primary tumor, to intravasation into blood circulatory system, arrest in a distant vascular bed, extravasation into the interstitium of a target organ, to intravasation into blood circulatory system, arrest in a distant vascular bed, extravasation into the interstitium of a target organ, and metastasis to the target organ. Stimulation of any of these steps can be expected to enhance malignant spread, whereas inhibition of any can be expected to reduce metastasis.

Obesity is a leading risk factor for cancer, second only to smoking. Being obese at the time of diagnosis of primary cancer can be predictive of poor prognosis. For example, breast cancer patients who are obese are at a greater risk of recurrence [10] with a shorter disease-free interval than those with normal body weight [11], and obese or overweight prostate cancer patients are more likely to have recurrence after radical prostatectomy than those of normal weight [12,13]. Adipose tissue has been considered an endocrine organ that produces adipokines contributing to obesity. The expression of the adipokine PAI-1 is elevated in obese subjects [14,15], and plasma levels of PAI-1 are elevated in mice fed obesigenic, high-fat diets [16,17]. We reported that a high-fat diet enhances the malignant spread of Lewis lung carcinoma (LLC) in mice and this enhancement is accompanied by increases in plasma concentrations of PAI-1 [18,19]. We hypothesized that PAI-1 participates in...
the spread of LLC and that the pro-metastatic effect of a high-fat feeding involves the up-regulation of PAI-1. The present experiments were conducted to test that hypothesis in PAI-1 deficient mice using a spontaneous metastasis model.

Materials and Methods

This study was approved by the Animal Care and Use Committee of the U.S. Department of Agriculture, Agricultural Research Service, Grand Forks Human Nutrition Research Center. The procedures followed the National Institute of Health guidelines for the care and use of laboratory animals [20].

Animals and diets

Four to five-week-old male PAI-1 deficient mice (PAI-1<sup>−/−</sup>, B6.129S2-Serpinel<sup>1ΔM1ΔE</sup>/J) with a C57BL/6J background and C57BL/6J wild-type mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The AIN93G diet [21] and AIN93G diet modified to include 45% of energy from dietary fat (hereafter referred to as the high-fat diet) were used in this study (Table 1). Gross energy of each diet (Table 1) was analyzed by oxygen bomb calorimetry (Model 6200, Oxygen Bomb Calorimeter, Parr Instrument, Moline, IL). Mice were shipped in two separate cohorts within 2 weeks. In each cohort, mice were randomized to 4 treatment groups (n = 11 per group for PAI-1<sup>−/−</sup> mice fed the AIN93G or the high-fat diet, n = 14 per group for wild-type mice fed the AIN93G or the high-fat diet). Mice were maintained in a pathogen-free room on a 12:12-hour light-dark cycle with a temperature of 22±1°C. Mice were weighed weekly, and they had free access to their diets and deionized water. Food intake was recorded for 3 weeks before cancer cell inoculation. All diets were powdered diets, and they were stored at −20°C until being provided to mice. Body composition was assessed in conscious, immobilized mice 1 week before cancer cell injection using quantitative magnetic resonance (Echo whole-body composition analyzer, Model 100, Echo Medical System, Houston, TX).

Lewis lung carcinoma cells

Lewis lung carcinoma cell line, a variant that metastasizes specifically to lungs [22], was obtained from Dr. Phina Brodt, McGill University, Montreal, Quebec, Canada. The cells were cultured with RPMI-1640 medium containing 10% heat-inactivated fetal bovine serum and maintained in a humidified atmosphere of 5% CO2 in air at 37°C. Cells used for animal studies were in vitro-selected once [19]. The cells were monitored for phenotype (by microscopic examination of cell morphology), proliferation properties (by growth curve analysis) and metastatic capability (by injecting cells subcutaneously into mice and examining metastatic formation in lungs). Cells were free of mycoplasma based on Hoechst DNA staining and direct culture tests performed by American Type Cell Collection (Manassas, VA). These assessments showed that cell identity and metastatic behavior were similar to those of original stocks from the institution providing the cell line.

Experimental design

Mice (n = 22 per group for PAI-1<sup>−/−</sup> mice, n = 28 per group for wild-type mice) were fed their respective AIN93G or high-fat diet for 7 weeks before they were subcutaneously injected with 2.5×10<sup>5</sup> viable LLC cells per mouse into the lower dorsal region. The resulting primary tumor was removed surgically 12 days later when it was approximately 1 cm in diameter. Following removal, the mice were maintained on their respective diets for an additional 10 days. An additional 13 wild-type mice were fed the AIN93G diet but not injected with LLC cells. At the end of the study, plasma was collected from these mice to use as a control in comparison with AIN93G-fed LLC-bearing wild-type mice to assess the effect of metastasis on changes in plasma concentrations of adipokines, angiogenic factors and related biomarkers. Mice

Table 1. Composition of experimental diets.

| Ingredient                  | AIN93G g | AIN93G kcal | High-Fat g | High-Fat kcal |
|-----------------------------|----------|------------|------------|---------------|
| Corn starch                 | 397.5    | 1590       | 33.5       | 134           |
| Casein                      | 200      | 800        | 200        | 800           |
| Sucrose                     | 100      | 400        | 100        | 400           |
| Dextrin                     | 132      | 528        | 200        | 800           |
| Corn oil                    | 70       | 630        | 201.5      | 1813.5        |
| Cellulose                   | 50       | 0          | 50         | 0             |
| AIN93 mineral mix*          | 35       | 30         | 35         | 30            |
| AIN93 vitamin mix*          | 10       | 39         | 10         | 39            |
| L-cystine                   | 3        | 12         | 3          | 12            |
| Choline bitartrate          | 2.5      | 0          | 2.5        | 0             |
| tert-butylhydroquinone      | 0.014    | 0          | 0.014      | 0             |
| Total                       |          | 1000       | 4029       | 835.5         | 4029          |
| Calculated composition fat  | 16       | 45         |            |               |

*Reference 21.
*<sup>n</sup> = 3 for each diet.

PLOS ONE | www.plosone.org 2 October 2014 | Volume 9 | Issue 10 | e110869
were terminated by intraperitoneal injection of a mixture of ketamine and xylazine. Lungs were removed and fixed with Bouin’s solution. The number of pulmonary metastases was counted [23] and the cross-sectional area and the volume of each metastasis were analyzed [24] using an ImagePro-Plus software (Media Cybernetics, Silver Spring, MD) and a camera-equipped stereomicroscope. Tumor cross-sectional area was defined as the surface area of each lung metastasis. Tumor volume was estimated by assuming that tumors were spherical and using their average diameter [24]. The average diameter was the average measured at two degree intervals joining two outline points and passing through the centroid. Epididymal adipose tissue and plasma were collected and stored at $2^\circ$C for further analyses.

Quantification of adipokines, angiogenic factors and related biomarkers

Concentrations of PAI-1 in epididymal adipose tissue, plasma and 24-hours-old conditioned medium from LLC cells were quantified using a sandwich enzyme-linked immunosorbent assay kit (Molecular Innovation, Novi, MI). An extract of adipose tissue was obtained by the protocol of Ortega et al [25]. Concentrations of PAI-1 in adipose extract and conditioned medium were normalized to protein content. Total protein concentration in each adipose extract and LLC cell lysate was estimated by BCA protein assay (Thermo Scientific, Waltham, MA). Monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), leptin, vascular endothelial growth factor (VEGF), tissue inhibitor of metalloproteinase-1 (TIMP-1) and collagenase-2 (uPA) (Cell Sciences, Canton, MA), insulin (all were from R&D Systems, Minneapolis, MN) and glucose (Cayman Chemical, Ann Arbor, MI) were quantified using sandwich enzyme-linked immunosorbent assay kits following manufacturers’ protocols. Samples were read within the linear range of the assay, and the accuracy of the analysis was confirmed by the controls provided in each kit.

Statistical Analyses

The effects of diet (AIN93G or high-fat), genotype (PAI-1$^{-/-}$ or wild-type) and their interaction were tested using two-way analysis of variance (ANOVA). If a significant interaction between diet and genotype occurred, Tukey contrasts were performed to compare the 4 treatment groups. To examine the effect of metastasis on changes of plasma concentrations of adipokines, angiogenic factors and related biomarkers, a priori contrasts were used to test for differences in wild-type mice fed the AIN93G diet with or without LLC. A mixed model ANOVA with mouse as the random blocking factor and with diet, genotype and their interaction as fixed effects was used to test for differences in cross-sectional area and volume of metastases among the groups. All data are presented as means ± standard error of the mean (SEM). Differences with a $p$-value of 0.05 or less were considered statistically significant. All analyses were performed using SAS software (version 9.3, SAS Institute, Cary, NC).

Results

Consumption of the high-fat diet increased body weights compared to the AIN93G diet. The difference was statistically significant 4 weeks after the initiation of experimental feeding ($p < 0.01$), and the significant increase continued throughout the experiment (Fig. 1). Starting at week 6, PAI-1$^{-/-}$ mice weighed significantly less than wild-type mice (PAI-1$^{-/-}$ vs. wild-type: $p < 0.05$, Fig. 1), a difference more marked in the high-fat fed mice. Compared to the AIN93G diet, high-fat diet consumption increased body fat mass by 43% (high-fat vs. AIN93G: $p < 0.01$) with a concomitant reduction in body lean mass by 9% ($p < 0.01$) (Table 2). Compared to wild-type mice,
Two-way ANOVA was performed to test for differences among the groups. Values are means ± SEM (n = 22 per group for PAI-1−/− mice, n = 28 per group for wild-type mice or n = 6 per group for caloric intake). AIN WT: AIN93G-fed wild-type mice, AIN PAI-1−/−: high-fat fed PAI-1−/− mice.

Subcutaneous injection of LLC cells resulted in primary tumor and pulmonary metastasis. Compared to the AIN93G diet, high-fat diet consumption increased the number of lung metastases by 60% (high-fat vs. AIN93G: p < 0.01; Fig. 2a). Mice deficient in PAI-1 had 35% less metastases than wild-type mice (PAI-1−/− vs. wild-type: p < 0.01; Fig. 2a). The high-fat diet increased tumor cross-sectional area by 82% (p < 0.05, Fig. 2b) and tumor volume by 130% (p < 0.05, Fig. 2c) in wild-type mice compared to AIN93G-fed controls. Deficiency in PAI-1 reduced tumor cross-sectional area by 52% (p < 0.05, Fig. 2b) and tumor volume by 61% (p < 0.05, Fig. 2c) in high-fat fed mice, but the deficiency did not affect either cross-sectional area or volume in mice fed the AIN93G diet (Fig. 2b, 2c), compared to their respective wild-type controls. Necropsy at the end of the study found no metastatic growth in other organs.

There was no significant difference in adipose PAI-1 between LLC-bearing and non-tumor-bearing mice fed the AIN93G diet (Table 3). Compared to the AIN93G diet, the high-fat diet increased adipose PAI-1 by 147% (p < 0.05, Table 3). Lewis lung carcinoma increased plasma PAI-1 by 407% in wild-type mice (Table 3). Plasminogen activator inhibitor-1 in adipose tissue and plasma was not detectable in PAI-1−/− mice regardless of the diet (Table 3). The conditioned medium from LLC cells contained 32.7 ± 7.7 ng PAI-1/mg protein (n = 6).

Plasma levels of uPA were increased in tumor-bearing mice by 115% compared to non-tumor-bearing controls (p < 0.01, Table 3). Compared to the AIN93G diet, the high-fat diet increased plasma uPA by 112% (high-fat vs. AIN93G: p < 0.01, Table 3). There was no significant difference in plasma uPA between PAI-1−/− and wild-type mice (Table 3).

Compared to non-tumor-bearing controls, mice with LLC had a 443% increase in plasma MCP-1 (p < 0.01) and a 397% increase in TNF-α (p < 0.01) (Table 3). The high-fat diet, compared to the AIN93G diet, increased MCP-1 by 144% (high-fat vs. AIN93G: p < 0.01) and TNF-α by 69% (high-fat vs. AIN93G: p < 0.01) (Table 3). Compared to wild-type mice, PAI-1−/− mice had a 24% increase in plasma MCP-1 (PAI-1−/− vs. wild-type: p < 0.01) and 7% increase in TNF-α (PAI-1−/− vs. wild-type: p < 0.05) (Table 3). Lewis lung carcinoma did not affect plasma levels of leptin (Table 3). The high-fat diet, compared to the AIN93G diet, increased plasma leptin by 106% (high-fat vs. AIN93G: p < 0.01, Table 3). Plasminogen activator inhibitor-1 deficiency increased leptin by 29% (PAI-1−/− vs. wild-type: p = 0.01, Table 3).

Mice with LLC exhibited an 11% increase in plasma concentrations of VEGF (p < 0.01) and a 47% increase in TIMP-1 (p < 0.01) compared to non-tumor-bearing controls (Table 4). The high-fat, compared to the AIN93G diet, increased plasma VEGF by 12% (high-fat vs. AIN93G: p = 0.01) and TIMP-1 by 71% (high-fat vs. AIN93G: p < 0.01) (Table 4). Deficiency in PAI-1 increased plasma VEGF by 11% (PAI-1−/− vs. wild-type: p < 0.05) and TIMP-1 by 27% (PAI-1−/− vs. wild-type: p < 0.01) (Table 4). There were no differences in plasma concentrations of insulin and glucose between LLC-bearing and non-tumor-bearing mice.
Table 4). The high-fat diet, compared to the AIN93G diet, increased plasma insulin by 111% (high-fat vs. AIN93G: \( p < 0.01 \)) and glucose by 23% (high-fat vs. AIN93G: \( p < 0.01 \)) (Table 4).

Deficiency in PAI-1 increased plasma insulin by 15% (PAI-1 \(^{-/-}\) vs. wild-type: \( p = 0.01 \), Table 4). There was no significant difference in plasma glucose between PAI-1 \(^{-/-}\) and wild-type mice (Table 4).

**Discussion**

The present study demonstrates that PAI-1 participates in spontaneous metastasis of LLC and that PAI-1 deficiency reduces metastasis enhanced by the high-fat diet.

Malignant spread is an important and critical step of metastatic development. The finding of a significant reduction in pulmonary metastases in PAI-1 \(^{-/-}\) mice indicates that host-produced PAI-1 may play an active role in metastasis. This is supported by previous reports that the absence of host PAI-1 prevents invasion of transplanted malignant keratinocytes in vivo [6]. Plasma concentrations of uPA in PAI-1 \(^{-/-}\) mice were similar to those of their wild-type counterparts, indicating that the action of PAI-1 on cancer spread may be independent on uPA. However, there is evidence suggesting that both PAI-1 and uPA are necessary for maximal metastatic progression. Lung cancer cells expressing only uPA and its receptor display no invasive capability [26].

When fed the high-fat diet, PAI-1 \(^{-/-}\) mice had a significant smaller metastasis size compared to the wild-type mice. This finding indicates that PAI-1 expression is needed for high-fat feeding enhancement of growth of metastases.

Adipose PAI-1 was depleted in PAI-1 \(^{-/-}\) mice, regardless of the diet. This finding indicates that it is the PAI-1 derived from adipose tissues that participates in LLC progression and contributes to enhanced malignant spread and growth by the high-fat diet. Although LLC produces PAI-1, the present results suggest that the amount of PAI-1 contributed by LLC in this model is insufficient to overcome the host deficiency of this adipokine. It indicates the importance of exogenous PAI-1 in metastasis of PAI-1 dependent malignancies.

The present study demonstrates that plasma concentrations of inflammatory cytokines (MCP-1, TNF-\(\alpha\), leptin), angiogenic factors (VEGF, TIMP-1) and insulin are elevated in PAI-1 \(^{-/-}\) mice. These elevations apparently compromise a compensation for the absence of PAI-1. Monocyte chemotactic protein-1 [27] and TNF-\(\alpha\) [20,29] are tumorigenic and angiogenic. Leptin is known...
### Table 3. Adipose concentration of PAI-1 and plasma concentrations of adipokines (PAI-1, MCP-1, TNF-α, leptin) and uPA1.

| Treatment | Control | AIN WT | AIN PAI-1-/- | HF WT | HF PAI-1-/- |
|-----------|---------|--------|-------------|-------|-------------|
| PAI-1, ng/mg protein | 0.22±0.03 | 0.17±0.04 | N.D. | 0.42±0.07 | N.D. |
| PAI-1, ng/mL | 0.44±0.10 | 2.23±0.30 | N.D. | 4.50±0.48 | N.D. |
| uPA, ng/mL | 0.82±0.08 | 1.76±0.20 | 1.51±0.23 | 3.77±0.35 | 3.15±0.33 |
| MCP-1, pg/mL | 7.32±1.97 | 39.77±4.85 | 43.21±2.29 | 87.77±3.65 | 114.88±8.32 |
| TNF-α, pg/mL | 1.93±0.64 | 9.60±0.30 | 10.53±0.32 | 16.51±0.39 | 17.49±0.47 |
| Leptin, ng/mL | 4.53±0.42 | 4.57±0.35 | 6.48±0.60 | 10.18±0.75 | 12.53±1.14 |

*p value for LLC-bearing groups (n = 10 per group). *p<0.01 compared to AIN WT. Diet: AIN93G-fed non-tumor-bearing wild-type mice, AIN PAI-1-/-: AIN93G-fed PAI-1-/- mice, HF WT: high-fat fed wild-type mice, HF PAI-1-/-: high-fat fed PAI-1-/- mice, D x G: diet x gene interaction. N.D.: not detectable.

### Table 4. Plasma concentrations of angiogenic factors (VEGF, TIMP-1), insulin and glucose1.

| Treatment | Control | AIN WT | AIN PAI-1-/- | HF WT | HF PAI-1-/- |
|-----------|---------|--------|-------------|-------|-------------|
| VEGF, pg/mL | 69.41±1.23 | 77.1±2.86 | 84.34±5.98 | 85.00±1.76 | 96.16±2.97 |
| TIMP-1, ng/mL | 0.81±0.04 | 1.19±0.09 | 1.49±0.08 | 2.01±0.10 | 2.57±0.11 |
| Insulin, ng/mL | 0.32±0.01 | 0.32±0.01b | 0.31±0.01b | 0.59±0.01b | 0.74±0.05a |
| Glucose, mg/mL | 0.84±0.04 | 0.82±0.04 | 0.87±0.03 | 1.08±0.03 | 1.00±0.03 |

*p value for LLC-bearing groups (n = 10 per group). *p<0.01 compared to AIN WT. Diet: AIN93G-fed non-tumor-bearing wild-type mice, AIN PAI-1-/-: AIN93G-fed PAI-1-/- mice, HF WT: high-fat fed wild-type mice, HF PAI-1-/-: high-fat fed PAI-1-/- mice, D x G: diet x gene interaction.
to be angiogenic [30] and to modulate tumor growth by increasing VEGF expression [31]. Vascular endothelial growth factor [32] and TIMP-1 [33] contribute to metastatic development. Hyperinsulinaemia enhances growth and progression of mammary tumors [34,35]. Thus, observed elevations of these factors suggest that they may contribute to the less aggressive development and growth of LLC in the absence of PAI-1 in PAI-1−/− mice. Plasminogen activator inhibitor-1 together with uPA has been recommended as prognostic biomarkers in breast cancer [36]. RNA aptamers specific to PAI-1 were generated for preclinical testing for potential clinical applications [37]. PAI-039, a small molecule inhibitor of PAI-1 that was investigated clinically for treatments of acute and arterial thrombosis [38], has been tested for its efficacy in preclinical tumor angiogenesis mouse models [39]. The present results suggest that treatments targeting PAI-1 may be counteracted by the compensatory overproduction of inflammatory cytokines and angiogenic factors. This warrants further investigation, particularly in those studies aimed at long-term PAI-1 inhibition.

That PAI-1 was not detectable in plasma from LLC-bearing PAI-1−/− mice suggests that LLC-produced PAI-1 is not responsible for the significant elevated plasma PAI-1 in AIN93G-fed wild-type mice with LLC. Plasminogen activator inhibitor-1 is an acute phase reactant [40]. The concentration of PAI-1 in mouse liver is relatively low [41]; however, PAI-1 gene expression in the liver is up-regulated markedly by endotoxin and inflammatory mediators [41,42]. Because cancer has an inflammatory component, the presence of LLC in wild-type mice may be up-regulating PAI-1 production from liver and other organs, resulting in significantly higher plasma PAI-1 than in the non-tumor-bearing wild-type mice.

Reductions in caloric intake and body fat mass in PAI-1−/− mice fed the high-fat diet may have contributed to the inhibition of malignant progression, particularly metastatic growth, in those mice. Dietary energy restriction reduces primary tumorigenesis and metastasis [43]. Caloric restriction, which lowers adiposity and production of inflammatory cytokines, may be a useful adjuvant in the prevention and treatment of obesity-related cancer. The present results suggest that better outcomes in studies aimed at PAI-1 inhibition may come from subjects with healthy body weights, whereas overweight/obesity or excessive caloric intake may be additive to PAI-1 deficiency-related compensatory increases in inflammatory cytokines and angiogenic factors.

Significant reduction in body fat mass and increases in plasma concentrations of leptin and insulin in PAI-1−/− mice were not expected considering the existing understanding that blood levels of leptin and insulin are positively associated with adiposity [44,45]. However, it has been reported that plasma insulin was increased in PAI-1−/− mice compared to wild-type mice, even though there was no difference in gonadal fat pad weight between the groups [46]. Considering the significant increases in adipokines and angiogenic factors in PAI-1−/− mice in the present study, the increase in leptin, as well as insulin, is likely through an overproduction compensatory mechanism in the absence of PAI-1, which may be independent of body fat mass or body weight.

That LLC-associated increases in plasma concentrations of inflammatory cytokines PAI-1, MCP-1, TNF-α, protease uPA and angiogenic factors VEGF, TIMP-1 indicate the aggressiveness of this carcinoma model. High expressions of PAI-1 [2,47], MCP-1 [48,49], TNF-α [50], uPA [2], VEGF [31] and TIMP-1 [52] have been associated with regional or distant metastasis and poor prognosis in cancer patients. Elevations of these cytokines [33,34,51], uPA [55,56] and angiogenic markers [19,33] have been reported in animal models of various malignancies. The present results are consistent with the existing knowledge and confirm the usefulness of the LLC model to study spontaneous metastasis.

The present study used corn oil as the source of dietary fat, which is comprised of 57% linoleic acid [57] and provided 23% of total energy in the high-fat diet. This diet was low in ω-linolenic acid (0.5% of dietary energy), which comprises 1% of fatty acids in corn oil [57]. It is possible that this low ω-linolenic acid/linoleic acid ratio [58] may have contributed to the effects observed for the high-fat diet because of its low content of ω-linolenic acid, which has been suggested to be anticarcinogenic [59,60]. This possibility warrants further investigation.

In summary, results from the present study indicate that PAI-1 contributes to the metastasis of LLC and that PAI-1 deficiency ameliorates metastasis enhanced by the high-fat diet. These findings are consistent with others showing that PAI-1 participates in cancer progression [3,4]. Furthermore, the present study demonstrates that host-produced PAI-1 including that from adipose tissues was a significant determinant of malignant progression. Adipose tissue is a modifiable source of PAI-1, particularly in obesity. Weight loss through caloric restriction alone or in combination with exercise reduces blood levels of PAI-1 [61,62]; thus, these practices can be useful adjuvants to achieving the best outcomes of chemoprevention. The compensatory increases in production of inflammatory cytokines, angiogenic factors and insulin in PAI-1−/− mice suggest that these compensatory responses may counteract treatments aimed at PAI-1 inhibition.

Acknowledgments

The authors greatly acknowledge the assistance of the following staff of Grand Forks Human Nutrition Research Center: Kay Keehr for technical support, James Linlauf for preparing experimental diets, LuAnn Johnson for advice in statistical analysis and vivarium staff for providing high quality animal care. Notes: The U.S. Department of Agriculture, Agricultural Research Service, Northern Plains Area, is an equal opportunity/affirmative action employer and all agency services are available without discrimination. Mention of trade names or commercial products in this article is solely for providing specific information and does not imply recommendation or endorsement by the U.S. Department of Agriculture.

Author Contributions

Conceived and designed the experiments: LY. Performed the experiments: LY. LD. Analyzed the data: LY. Contributed reagents/materials/analysis tools: LY. LD. Contributed to the writing of the manuscript: LY.

References

1. Janicke F, Schmitt M, Pacher L, Ulm K, Harbeck N, et al. (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 193–208.
2. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. (2003) Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 82: 184–193.
3. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, et al. (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276: 33964–33966.
4. Tsuchiya H, Sunayama C, Okada G, Matsuda E, Tomita K, et al. (1997) Plasminogen activator inhibitor-1 accelerates lung metastasis formation of human fibrosarcoma cells. Anticancer Res 17: 313–316.
5. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Hoplis VA, et al. (2000) Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator.
plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 60: 5839–5847.

6. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, et al. (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4: 923–928.

7. Maillard CM, Bouquet C, Petitjean MM, Mestdagh M, Frau E, et al. (2008) Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors. Carcinogenesis 29: 2236–2242.

8. Ahlhold K, Nielsen BS, Frandsen TL, Brunner N, Dao N, et al. (2003) Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 22: 4389–4397.

9. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg (1998) Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87: 4718–4722.

10. Daniell HW (1983) Increased lymph node metastases at mastectomy for breast cancer associated with host obesity, cigarette smoking, age, and large tumor size. Cancer 62: 429–435.

11. Loi S, Milhe RL, Friedlander ML, McCredie MR, Giles GG, et al. (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14: 1681–1691.

12. Bassett WW, Cooperberg MR, Sadesky N, Silva S, BuChane J, et al. (2005) Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 66: 1060–1065.

13. Ameling CL, Rifenburgh RH, Sun L, Moul JW, Lance RS, et al. (2004) Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22: 439–445.

14. McNeill JB, Schneider DJ, Arken CL, Lucore CL, Sobel BE (1994) Factors responsible for impaired fibroblin in obese subjects and NIDDM patients. Diabetes 43: 104–109.

15. Allesi MC, Bastelica D, Morange P, Berthet B, Leduc I, et al. (2000) Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, et al. (2004) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14: 1681–1691.

16. Yan L, Combs GF Jr (2014) Consumption of a high-fat diet abrogates inhibitory signaling inhibition results in efficient anti-tumor activity in estrogen receptor negative breast cancer. Oncogene 22: 439–445.

17. Yan L, Graef GL, Claycombe KJ, Johnson LK (2013) Effects of voluntary running on spontaneous metastasis of Lewis lung carcinoma in mice. Clin Exp Metastasis 27: 581–590.

18. Yan L, Graef GL, Claycombe KJ, Johnson LK (2013) Effects of voluntary running and soy supplementation on diet-induced metabolic disturbances and inflammation in mice. J Agric Food Chem 61: 9371–9379.

19. Yan L, Combs GF Jr (2014) Consumption of a high-fat diet abrogates inhibitory effects of methylthionine on spontaneous metastasis of Lewis lung carcinoma in mice. Carcinogenesis 35: 2308–2313.

20. Yan L, Demars LC (2010) Effects of dietary fat on spontaneous metastasis of Lewis lung carcinoma in mice. Clin Exp Metastasis 27: 381–389.

21. Institute for Laboratory Animal Research (2011) Guide for the Care and Use of Laboratory Animals. National Research Council, Council for the Care and Use of Laboratory Animals, National Research Council, Institute for Laboratory Animal Research, editor. Washington, D.C.: National Academies Press.

22. Reeves PG, Nielsen FH, Fahey GJ (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123: 1939–1951.

23. Brod P (1986) Characterization of two highly metastatic variants of Lewis lung carcinoma with different organ specificities. Cancer Res 46: 2442–2448.

24. Fidler IJ (1978) General considerations for studies of experimental cancer metastasis. In: Busch H, editor. Methods in Cancer Research. New York: Plenum Press.

25. Ortega FJ, Moreno-Navarrete JM, Mayas D, Garcia-Santos E, Gomez-Serrano (1998) Overexpression of matrix metalloproteinase (MMP)-9 correlates with metastatic potential of human prostate cancer cells. Invasion Metastasis 3: 65–80.

26. Staiger H, Tschritter O, Machann J, Thamer C, Fritsche A, et al. (2003) The role of SOCS-3 and PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 20: 1153–1158.

27. Czakay RM, Loskutoff DJ (2004) Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 229: 1090–1096.

28. Yan L, DeMars LC, Johnson LC (2012) Long-term voluntary running improves diet-induced adiposity in young adult mice. Nutr Res 32: 458–465.

29. Staiger H, Tschritter O, Machann J, Thamer C, Fritsche A, et al. (2003) Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 11: 368–372.

30. Schwartz MW, Woods SG, Porte D Jr, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404: 661–671.

31. Herbemont R, Bezchlibnyk-Butt M, Williams LE, Jones RA, Claffey KP (2010) Obesity energy availability affects primary and metastatic breast cancer and metastasist efficiency. Breast Cancer Res Treat 133: 333–344.

32. Staiger H, Tschritter O, Machann J, Fritsche A, et al. (2003) Involvement of very late activation antigen 4 (VLA-4) and vascular cell adhesion molecule 1 in metastasis. In: Busch H, editor. Methods in Cancer Research. New York: Plenum Press.

33. Corn Refiners Association. Corn Oil (5th Edition, 2006). Corn Refiners Association. 2006/12/CornOil.pdf. 1–22. Accessed 2014 Oct 7.

34. Dool CJ, Mashiedi H, Zakikhani M, David S, Zhao Y, et al. (2011) IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than aloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-resistant breast cancer. Endocr Relat Cancer 18: 689–709.

35. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D (2010) Insulin-sensing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 59: 686–693.

36. Haris I, Fritsche H, Menzel R, Norton L, Ravdin P, et al. (2007) American Society of Clinical Oncology update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5207–5312.

37. Kaidoh EK, Guduchetch A, Bachmann F (1988) Plasminogen activator inhibitor-1 and plasminogen activator inhibitor-2 in various disease states. Thromb Haemost 79: 7–12.

38. Corn Refiners Association. Corn Oil (5th Edition, 2006). Corn Refiners Association. 2006/12/CornOil.pdf. 1–22. Accessed 2014 Oct 7.
59. Gerber M (2012) Omega-3 fatty acids and cancer: a systematic update review of epidemiological studies. Br J Nutr 107 Suppl 2: S228–239.

60. Algamas-Dimantov A, Davidovsky D, Ben-Ari J, Kang JX, Peri I, et al. (2012) Amelioration of diabesity-induced colorectal ontogenesis by omega-3 fatty acids in mice. J Lipid Res 53: 1056–1070.

61. Kockx M, Leenen R, Seidell J, Princen HM, Kooistra T (1999) Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss. Thromb Haemost 82: 1490–1496.

62. Mavri A, Stegnar M, Krebs M, Sentocnik JT, Geiger M, et al. (1999) Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 19: 1582–1587.